Hepatitis Monthly

Published by: Kowsar

A Meta-Analysis of the Association Between the I148M Variant of Patatin-Like Phospholipase Domain Containing 3 Gene and the Presence of Chronic Hepatitis C

Haiying Zhang 1 , 2 , * , Li Xue 1 , 2 , Lizhen Chen 3 , Shunshun Jiang 1 , 2 , Yongning Xin 4 and Shiying Xuan 4 , *
Authors Information
1 Department of Gastroenterology, The Second Affiliated Hospital of Medical College, Qingdao University, Qingdao, China
2 Department of Gastroenterology, Qingdao Central Hospital, Qingdao, China
3 Medical College, Qingdao University, Qingdao, China
4 Department of Gastroenterology, Qingdao Municipal Hospital, Qingdao, China
Corresponding Authors:
Article information
  • Hepatitis Monthly: November 01, 2015, 15 (11); e31987
  • Published Online: November 28, 2015
  • Article Type: Review Article
  • Received: August 1, 2015
  • Revised: September 20, 2015
  • Accepted: October 2, 2015
  • DOI: 10.5812/hepatmon.31987

To Cite: Zhang H, Xue L, Chen L, Jiang S, Xin Y, et al. A Meta-Analysis of the Association Between the I148M Variant of Patatin-Like Phospholipase Domain Containing 3 Gene and the Presence of Chronic Hepatitis C, Hepat Mon. 2015 ; 15(11):e31987. doi: 10.5812/hepatmon.31987.

Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. Khodabandehloo M, Roshani D. Prevalence of hepatitis C virus genotypes in Iranian patients: a systematic review and meta-analysis. Hepat Mon. 2014; 14(12)[DOI][PubMed]
  • 2. Seeff LB. The history of the "natural history" of hepatitis C (1968-2009). Liver Int. 2009; 29 Suppl 1: 89-99[DOI][PubMed]
  • 3. Urabe Y, Ochi H, Kato N, Kumar V, Takahashi A, Muroyama R, et al. A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region. J Hepatol. 2013; 58(5): 875-82[DOI][PubMed]
  • 4. Asselah T, Bieche I, Sabbagh A, Bedossa P, Moreau R, Valla D, et al. Gene expression and hepatitis C virus infection. Gut. 2009; 58(6): 846-58[DOI][PubMed]
  • 5. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008; 40(12): 1461-5[DOI][PubMed]
  • 6. Ke PY, Chen SS. Hepatitis C virus and cellular stress response: implications to molecular pathogenesis of liver diseases. Viruses. 2012; 4(10): 2251-90[DOI][PubMed]
  • 7. Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology. 2009; 137(2): 549-57[DOI][PubMed]
  • 8. Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, Romeo S, et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol. 2013; 19(41): 6969-78[DOI][PubMed]
  • 9. Singal AG, Manjunath H, Yopp AC, Beg MS, Marrero JA, Gopal P, et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol. 2014; 109(3): 325-34[DOI][PubMed]
  • 10. Zampino R, Florio A, Coppola N, Cirillo G, Macera M, Marrone A, et al. PNPLA3 I148M variant as a risk factor for carotid atherosclerosis in chronic hepatitis C. Int J Cardiol. 2014; 172(1): 291-2[DOI][PubMed]
  • 11. Sookoian S, Gianotti TF, Gonzalez CD, Pirola CJ. Association of the C-344T aldosterone synthase gene variant with essential hypertension: a meta-analysis. J Hypertens. 2007; 25(1): 5-13[DOI][PubMed]
  • 12. Conn VS, Rantz MJ. Research methods: managing primary study quality in meta-analyses. Res Nurs Health. 2003; 26(4): 322-33[DOI][PubMed]
  • 13. Huwiler-Muntener K, Juni P, Junker C, Egger M. Quality of reporting of randomized trials as a measure of methodologic quality. JAMA. 2002; 287(21): 2801-4[PubMed]
  • 14. Nischalke HD, Berger C, Luda C, Berg T, Muller T, Grunhage F, et al. The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS One. 2011; 6(11)[DOI][PubMed]
  • 15. Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology. 2011; 53(3): 791-9[DOI][PubMed]
  • 16. Miyashita M, Ito T, Sakaki M, Kajiwara A, Nozawa H, Hiroishi K, et al. Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C. J Viral Hepat. 2012; 19(9): 608-14[DOI][PubMed]
  • 17. Valenti L, Rametta R, Ruscica M, Dongiovanni P, Steffani L, Motta BM, et al. The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterol. 2012; 12: 111[DOI][PubMed]
  • 18. Ezzikouri S, Alaoui R, Tazi S, Nadir S, Elmdaghri N, Pineau P, et al. The adiponutrin I148M variant is a risk factor for HCV-associated liver cancer in North-African patients. Infect Genet Evol. 2014; 21: 179-83[DOI][PubMed]
  • 19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials. 1986; 7(3): 177-88[DOI]
  • 20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109): 629-34[PubMed]
  • 21. He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010; 285(9): 6706-15[DOI][PubMed]
  • 22. Huang Y, He S, Li JZ, Seo YK, Osborne TF, Cohen JC, et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A. 2010; 107(17): 7892-7[DOI][PubMed]
  • 23. Pirazzi C, Adiels M, Burza MA, Mancina RM, Levin M, Stahlman M, et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol. 2012; 57(6): 1276-82[DOI][PubMed]
  • 24. Kumari M, Schoiswohl G, Chitraju C, Paar M, Cornaciu I, Rangrez AY, et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab. 2012; 15(5): 691-702[DOI][PubMed]
  • 25. Trepo E, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, Gustot T, et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology. 2011; 54(1): 60-9[DOI][PubMed]
  • 26. Corradini SG, Burza MA, Molinaro A, Romeo S. Patatin-like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma. Hepatology. 2011; 53(5): 1776[DOI][PubMed]
  • 27. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006; 130(6): 1636-42[DOI][PubMed]
  • 28. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008; 49(4): 634-51[DOI][PubMed]
  • 29. Walsh MJ, Vanags DM, Clouston AD, Richardson MM, Purdie DM, Jonsson JR, et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology. 2004; 39(5): 1230-8[DOI][PubMed]
  • 30. Sterne JA, Juni P, Schulz KF, Altman DG, Bartlett C, Egger M. Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research. Stat Med. 2002; 21(11): 1513-24[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments